Key Points
- Brian Caveney, Labcorp's EVP, sold 1,500 shares on Feb. 24 at an average price of $286.31 for $429,465, reducing his stake by 4.75% to 30,107 shares (≈$8.62M) as disclosed in an SEC Form 4.
- Labcorp reported quarterly EPS of $4.07, beating estimates while revenue was $3.52B (slightly below expectations), and set FY2026 EPS guidance of 17.55–18.25.
- The company declared a quarterly $0.72 dividend (annualized $2.88, ~1.0% yield; ex-dividend Feb. 27), while analysts hold a consensus "Moderate Buy" with an average price target of $304.42 and institutional ownership around 95.9%.
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) EVP Brian Caveney sold 1,500 shares of Labcorp stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the sale, the executive vice president owned 30,107 shares of the company's stock, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Labcorp Stock Performance
Labcorp stock opened at $287.48 on Friday. The company has a market cap of $23.83 billion, a PE ratio of 27.48, a PEG ratio of 1.93 and a beta of 1.03. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72. The company's 50-day moving average is $267.77 and its two-hundred day moving average is $269.86.
Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company had revenue of $3.52 billion during the quarter, compared to analysts' expectations of $3.56 billion. During the same quarter in the previous year, the company earned $3.45 EPS. Labcorp's revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.
Labcorp Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. Labcorp's dividend payout ratio is 27.53%.
Hedge Funds Weigh In On Labcorp
Several institutional investors have recently modified their holdings of the business. MidFirst Bank bought a new stake in Labcorp during the 4th quarter worth approximately $150,000. River Road Asset Management LLC boosted its holdings in shares of Labcorp by 13.4% in the fourth quarter. River Road Asset Management LLC now owns 408,256 shares of the medical research company's stock valued at $102,423,000 after buying an additional 48,274 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of Labcorp by 2.6% in the fourth quarter. Pacer Advisors Inc. now owns 313,702 shares of the medical research company's stock valued at $78,702,000 after buying an additional 7,956 shares during the period. Virtu Financial LLC bought a new stake in shares of Labcorp during the fourth quarter worth $1,677,000. Finally, Invesco Ltd. increased its position in shares of Labcorp by 7.1% during the fourth quarter. Invesco Ltd. now owns 1,391,978 shares of the medical research company's stock worth $349,220,000 after acquiring an additional 91,867 shares in the last quarter. Institutional investors own 95.94% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently commented on LH. Morgan Stanley reiterated an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Robert W. Baird boosted their target price on Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, February 10th. Wall Street Zen raised shares of Labcorp from a "hold" rating to a "buy" rating in a research note on Friday, January 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $304.42.
View Our Latest Stock Analysis on LH
About Labcorp
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
